Furosemide Decreases Serum Sodium
Furosemide causes hyponatremia (low serum sodium) through enhanced sodium excretion in the urine and dilutional effects from water retention. This is a well-established adverse effect that requires regular monitoring, particularly during initiation and dose escalation.
Mechanism of Sodium Loss
Furosemide inhibits sodium and chloride reabsorption in the ascending limb of the loop of Henle 1. This potent natriuretic effect leads to:
- Direct urinary sodium losses through blocked tubular reabsorption
- Activation of the renin-angiotensin-aldosterone system in response to volume depletion, which paradoxically can worsen hyponatremia through increased water retention 2
- Enhanced distal sodium delivery that promotes exchange with other cations 2
Clinical Significance and Monitoring
All patients receiving furosemide therapy should be observed for signs of hyponatremia, including dryness of mouth, thirst, weakness, lethargy, drowsiness, restlessness, muscle pains or cramps, and hypotension 3.
Monitoring Requirements:
- Serum electrolytes (particularly sodium) should be determined frequently during the first few months of therapy and periodically thereafter 3
- In heart failure patients on diuretics, measure serum sodium every 5-7 days after initiation until values are stable, then every 3-6 months 4
- In cirrhosis patients, periodic monitoring is essential, especially during the first month of treatment 5
Severity Thresholds and Management
Severe hyponatremia (serum sodium <120-125 mmol/L) warrants discontinuation of all diuretics 5, 6. The guidelines provide clear cutoffs:
- Mild hyponatremia: 130-135 mmol/L
- Moderate hyponatremia: 125-129 mmol/L
- Severe hyponatremia: <125 mmol/L 6
In cirrhosis with ascites, fluid restriction should be considered when serum sodium drops below 120-125 mmol/L 7. However, fluid restriction alone only modestly improves hyponatremia and is often poorly tolerated 6, 8.
Context-Specific Considerations
Heart Failure:
Loop diuretics including furosemide can cause hyponatremia, which complicates management 9. The risk is enhanced when two diuretics are used in combination due to increased sodium delivery to distal tubules 2, 4.
Cirrhosis with Ascites:
Hyponatremia occurs in approximately 21.6% of cirrhotic patients and is associated with higher prevalence of refractory ascites, hepatic encephalopathy, and mortality 6. Hypervolemic hyponatremia is more common in cirrhosis, resulting from non-osmotic vasopressin release and impaired free water clearance 6.
Pediatric Populations:
In premature infants with chronic lung disease, repeated furosemide administration causes sodium depletion, and those who develop hyponatremia exhibit higher incidence of hypertension and lower growth rates 1.
Critical Pitfalls
Do not assume hyponatremia is always dilutional - distinguish between hypovolemic hyponatremia (from overzealous diuresis) and hypervolemic hyponatremia (from underlying disease) 6
Hypovolemic hyponatremia requires volume expansion with normal saline and cessation of diuretics, not fluid restriction 6
Combining furosemide with ACE inhibitors or ARBs increases risk of severe hypotension and renal dysfunction 3
NSAIDs block furosemide's natriuretic effects and should be avoided 3
Recent research confirms that furosemide significantly increases urinary sodium excretion with corresponding decreases in extracellular water 10, and in patients with syndrome of inappropriate antidiuresis (SIAD), furosemide combined with fluid restriction did not show additional benefit over fluid restriction alone for correcting hyponatremia 11.